Citations

Clear

4796 citation(s) found for "Yu, Jennifer".

RB but not R‐HCVAD is a feasible induction regimen prior to auto‐HCT in frontline MCL: results of SWOG Study S1106
Chen, Robert W., Bernstein, Steven H., Kahwash, Samir B. , Forman, Stephen J. , Shea, Thomas C., Cashen, Amanda F. , Blum, Kristie A. , Fenske, Timothy S. , Fisher, Richard I., Cheson, Bruce D. , Smith, Sonali M. , Faham, Malek, Wilkins, Jennifer, Leonard, John P. , Friedberg, Jonathan W. , Li, Hongli , Rimsza, Lisa M. , Constine, Louis S , Barr, Paul M. , Phillips, Tycel , LeBlanc, Michael , Kahl, Brad S. , Kahwash, Samir B

Mayo Clinic

British Journal of Haematology | December 19, 2016 | Volume: 176 | Issue: 5 | Pages: 759-769

10.1111/bjh.14480 | PMID 27992063 Get It

SummaryAggressive induction chemotherapy followed by autologous haematopoietic stem cell transplant (auto‐HCT) is effective for younger patients with mantle cell lymphoma (MCL). However, the optimal induction regimen is widely debated. The Southwestern Oncology Group S1106 trial was designed to assess rituximab plus hyperCVAD/MTX/ARAC (hyperfractionated cyclophosphamide, vincristine, doxorubicin and dexamethasone, alternating with high dose cytarabine and methotrexate) (RH) versus rituximab plus bendamustine (RB) in a randomized phase II trial to select a pre‐transplant induction regimen for future development. Patients had previously untreated stage III, IV, or bulky stage II MCL and received either 4 cycles of RH or 6 cycles of RB, followed by auto‐HCT. Fifty‐three of a planned 160 patients were accrued; an unacceptably high mobilization failure rate (29%) on the RH arm prompted premature study closure. The estimated 2‐year progression‐free survival (PFS) was 81% vs. 82% and overall survival (OS) was 87% vs. 88% for RB and RH, respectively. RH is not an ideal platform for future multi‐centre transplant trials in MCL. RB achieved a 2‐year PFS of 81% and a 78% MRD negative rate. Premature closure of the study limited the sample size and the precision of PFS estimates and MRD rates. However, RB can achieve a deep remission and could be a platform for future trials in MCL.
Reporting quality and risk of bias in randomised trials in health professions education
Horsley, Tanya , Galipeau, James , Zeiter, Jeanie, Hamstra, Stanley J. , Cook, David A. , Hamstra, Stanley J , Petkovic, Jennifer

Mayo Clinic

Medical Education | December 17, 2016 | Volume: 51 | Issue: 1 | Pages: 61-71

10.1111/medu.13130 | PMID 27981660 Get It

Context Complete reporting of research is essential to enable consumers to accurately appraise, interpret and apply findings. Quality appraisal checklists are giving way to tools that judge the risk for bias. Objectives We sought to determine the prevalence of these complementary aspects of research reports (completeness of reporting and perceived risk for bias) of randomised studies in health professions education. Methods We searched bibliographic databases for randomised studies of health professions education. We appraised two cohorts representing different time periods (2008–2010 and 2014, respectively) and worked in duplicate to apply the CONSORT guidelines and Cochrane Risk of Bias tool. We explored differences between time periods using independent‐samples t ‐tests or the chi‐squared test, as appropriate. Results We systematically identified 180 randomised studies (2008–2010, n = 150; 2014, n = 30). Frequencies of reporting of CONSORT elements within full‐text reports were highly variable and most elements were reported in fewer than 50% of studies. We found a statistically significant difference in the CONSORT reporting index (maximum score: 500) between the 2008–2010 (mean ± standard deviation [SD]: 242.7 ± 55.6) and 2014 (mean ± SD: 311.6 ± 53.2) cohorts (p < 0.001). High or unclear risk for bias was most common for allocation concealment (157, 87%) and blinding of participants (147, 82%), personnel (152, 84%) and outcome assessors (112, 62%). Most risk for bias elements were judged to be unclear (range: 51–84%). Risk for bias elements significantly improved over time for blinding of participants (p = 0.007), incomplete data (p < 0.001) and the presence of other sources of bias (p < 0.001). Conclusions Reports of randomised studies in health professions education frequently omit elements recommended by the CONSORT statement. Most reports were assessed as having a high or unclear risk for bias. Greater attention to how studies are reported at study outset and in manuscript preparation could improve levels of complete transparent reporting.
The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group
Anderson, Deverick J. , Jenkins, Timothy C , Harris, Anthony D. , Weinstein, Robert A. , Han, Jennifer , Banerjee, Ritu , Patel, Robin , Zaoutis, Theoklis E., Lautenbach, Ebbing , Evans, Scott , Tamma, Pranita D. , Patel, Robin , Evans, Scott R

Mayo Clinic

Clinical Infectious Diseases | December 8, 2016 | Volume: 64 | Issue: suppl_1 | Pages: S36-S40

10.1093/cid/ciw830 | PMID 28350902 Get It

SOS2 and ACP1 Loci Identified through Large-Scale Exome Chip Analysis Regulate Kidney Development and Function
Li, Man , Weeks, Olivia , Mijatovic, Vladan, Teumer, Alexander , Tromp, Gerard , Fuchsberger, Christian , Gorski, Mathias , Nutile, Teresa , Sedaghat, Sanaz , Sorice, Rossella , Arking, Dan E. , Bihlmeyer, Nathan A. , Böger, Carsten A., Carroll, Robert J. , Cornelis, Marilyn C., Faul, Jessica D. , Feitosa, Mary F. , Gambaro, Giovanni , Gasparini, Paolo , Giulianini, Franco, Heid, Iris M. , Huang, Jinyan , Imboden, Medea , Jeff, Janina M., Jhun, Min A., Katz, Ronit , Kifley, Annette , Kilpeläinen, Tuomas O. , Laakso, Markku , Li‐Gao, Ruifang , Lohman, Kurt, Lu, Yingchang , Mägi, Reedik , Mihailov, Evelin, Mohlke, Karen L. , Mook‐Kanamori, Dennis O. , Robino, Antonietta , Salvi, Erika , Schick, Ursula M., Schulz, Christina‐Alexandra , Smith, Albert V. , Traglia, Michela , Yerges-Armstrong, Laura M. , Goodarzi, Mark O. , Kraja, Aldi T., Wessel, Jennifer , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Boerwinkle, Eric , Borecki, Ingrid B. , Bork‐Jensen, Jette , Böttinger, Erwin P. , Braga, Daniele , Brandslund, Ivan , Brody, Jennifer A. , Carey, David J. , Christensen, Cramer, Crook, Errol D., Boer, Ian H. de , Vries, Aiko P. J. de , Devuyst, Olivier , Dreisbach, Albert W. , Endlich, Karlhans , Franco, Oscar H. , Glümer, Charlotte , Gottesman, Omri, Grarup, Niels , Guðnason, Vilmundur , Harris, Tamara B., Hofman, Albert , Husemoen, Lise Lotte N. , Jackson, Rebecca D. , Jørgensen, Marit E. , Kähönen, Mika , Kardia, Sharon L. R., König, Wolfgang , Kriebel, Jennifer , Lauritzen, Torsten , Lehtimäki, Terho , Levy, Daniel , Linksted, Pamela , Loos, Ruth J. F. , Lupo, Antonio , Meisinger, Christine, Melander, Olle , Mitchell, Paul, Nauck, Matthias, Orho‐Melander, Marju , Parsa, Afshin, Pedersen, Oluf , Peters, Annette , Peters, Ulrike , Polašek, Ozren , Qi, Lu , Reiner, Alex P. , Rettig, Rainer, Ridker, Paul M., Rivadeneira, Fernando , Rossouw, Jacques E. , Schmidt, Frank , Soranzo, Nicole , Strauch, Konstantin , Toniolo, Daniela , Uitterlinden, André G. , Ulivi, Sheila , Velayutham, Dinesh , Völker, Uwe , Völzke, Henry , Waldenberger, Mélanie , Wang, Jie Jin , Weir, David R. , Witte, Daniel R. , Kuivaniemi, Helena , Fox, Caroline S., Franceschini, Nora , Goessling, Wolfram , Köttgen, Anna , Chu, Audrey Y., Rudan, Igor , Vasan, Ramachandran S. , Duijn, Cornelia M. van , Zhao, Wei , Padmanabhan, Sandosh , Lindgren, Cecilia M. , Franks, Paul W. , Weiß, Stefan , Langenberg, Claudia , Hattersley, Andrew T. , Turner, Stephen T. , Li, Yong , Huffman, Jennifer E. , Lyytikäinen, Leo‐Pekka , Tin, Adrienne , Yang, Qiong , Ahluwalia, Tarunveer S. , Chasman, Daniel I. , Dehghan, Abbas , Jackson, Anne , Kumar, Ashish , Malerba, Giovanni , Ruderfer, Douglas , Smith, Jennifer A. , Zhao, Wei , Liu, Chunyu , Group,, CHARGE Glycemic-T2D Working, Group,, CHARGE Blood Pressure Working, Campbell, Archie I , Coresh, Josef , Curhan, Gary C. , Cusi, Daniele , Denny, Joshua C. , Esko, Tõnu , Fülöp, Tibor , Gerhard, Glenn S. , Hansen, Torben , Hayward, Caroline , Hocking, Lynne J. , Hu, Frank B. , Jørgensen, Torben , Kooperberg, Charles , Launer, Lenore J. , Linneberg, Allan , Liu, Ching‐Ti , Meisinger, Christine, Metspalu, Andres , Nürnberg, Peter , Porteous, David John , Probst-Hensch, Nicole M , Psaty, Bruce M. , Raitakari, Olli Tuomas , Siscovick, David S. , Weiss, Stefan , Völker, Uwe , Teumer, Alexander , van Duijn, Cornelia M , Vasan, Ramachandran S , Smith, Albert V , Loos, Ruth J F , Li-Gao, Ruifang , Brody, Jennifer A , Padmanabhan, Sandosh , Levy, Daniel , de Vries, Aiko P J , Devuyst, Olivier; https://orcid.org/0000-0003-3744-4767

Mayo Clinic

Journal of the American Society of Nephrology | December 5, 2016 | Volume: 28 | Issue: 3 | Pages: 981-994

10.1681/asn.2016020131 | PMID 27920155 Get It

Genome-wide association studies have identified >50 common variants associated with kidney function, but these variants do not fully explain the variation in eGFR. We performed a two-stage meta-analysis of associations between genotypes from the Illumina exome array and eGFR on the basis of serum creatinine (eGFRcrea) among participants of European ancestry from the CKDGen Consortium ( n Stage1 : 111,666; n Stage2 : 48,343). In single-variant analyses, we identified single nucleotide polymorphisms at seven new loci associated with eGFRcrea ( PPM1J , EDEM3, ACP1, SPEG, EYA4, CYP1A1 , and ATXN2L ; P Stage1 <3.7×10 −7 ), of which most were common and annotated as nonsynonymous variants. Gene-based analysis identified associations of functional rare variants in three genes with eGFRcrea, including a novel association with the SOS Ras/Rho guanine nucleotide exchange factor 2 gene, SOS2 ( P =5.4×10 −8 by sequence kernel association test). Experimental follow-up in zebrafish embryos revealed changes in glomerular gene expression and renal tubule morphology in the embryonic kidney of acp1- and sos2 -knockdowns. These developmental abnormalities associated with altered blood clearance rate and heightened prevalence of edema. This study expands the number of loci associated with kidney function and identifies novel genes with potential roles in kidney formation.
The Alzheimer's Disease Neuroimaging Initiative 3: Continued innovation for clinical trial improvement
Weiner, Michael W. , Veitch, Dallas P. , Aisen, Paul , Cairns, Nigel J. , Harvey, Danielle, Jack, Clifford R. , Jagust, William J. , Morris, John C. , Petersen, Ronald C. , Salazar, Jennifer, Saykin, Andrew J. , Shaw, Leslie M. , Trojanowski, John Q. , Initiative, Alzheimer's Disease Neuroimaging, Harvey, Danielle , Beckett, Laurel , Green, Robert C. , Harvey, Danielle, Toga, Arthur W. , Initiative, Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J

Mayo Clinic

Alzheimer's & Dementia | December 5, 2016 | Volume: 13 | Issue: 5 | Pages: 561-571

10.1016/j.jalz.2016.10.006 | PMID 27931796 Get It

Abstract Introduction The overall goal of the Alzheimer's Disease Neuroimaging Initiative (ADNI) is to validate biomarkers for Alzheimer's disease (AD) clinical trials. ADNI‐3, which began on August 1, 2016, is a 5‐year renewal of the current ADNI‐2 study. Methods ADNI‐3 will follow current and additional subjects with normal cognition, mild cognitive impairment, and AD using innovative technologies such as tau imaging, magnetic resonance imaging sequences for connectivity analyses, and a highly automated immunoassay platform and mass spectroscopy approach for cerebrospinal fluid biomarker analysis. A Systems Biology/pathway approach will be used to identify genetic factors for subject selection/enrichment. Amyloid positron emission tomography scanning will be standardized using the Centiloid method. The Brain Health Registry will help recruit subjects and monitor subject cognition. Results Multimodal analyses will provide insight into AD pathophysiology and disease progression. Discussion ADNI‐3 will aim to inform AD treatment trials and facilitate development of AD disease‐modifying treatments.
How Asking about the Best Ice Cream Reveals Ourselves
Ng, J. , NG, JENNIFER

Mayo Clinic

Ethnographic Praxis in Industry Conference Proceedings | November 30, 2016 | Volume: 2016 | Issue: 1 | Pages: 550-550

10.1111/1559-8918.2016.01124 Get It

As an author of a book about ice cream around the world, I am often asked this question: What is the best ice cream? I am often stumped. I know that they want something that they don't know from the “expert”. So when I hesitantly answer, I would give my personal favorite, one that I discovered during my travels—a goat cheese ice cream with roasted cherries from Jeni's Ice Cream in Columbus, Ohio.Yet I was curious—why do people ask that question if it could be potentially disappointing? Do they really want the #1 based on my personal opinion? Did they want to find something new to try? Were they trying to understand my motivation? Were they curious about a story? I unravel this question through an investigation of the intention of the question. When applied to ethnography, how does that question apply? As ethnographers, do we miss an important insight if we don't ask about the best?
Guideline for Reversal of Antithrombotics in Intracranial Hemorrhage: Executive Summary. A Statement for Healthcare Professionals From the Neurocritical Care Society and the Society of Critical Care Medicine
Frontera, Jennifer , Lewin, John J. , Aisiku, Imo, Alexandrov, Anne W. , Cook, Aaron M. , Zoppo, Gregory J. del, Kumar, Monisha A. , Stiefel, Michael , Teitelbaum, Jeanne , Wartenberg, Katja E. , Zerfoss, Cindy, Frontera, Jennifer A, Rabinstein, Alejandro A. , Aisiku, Imoigele P. , Peerschke, Ellinor I.B. , Cook, Aaron M , Frontera, Jennifer

Mayo Clinic

Critical Care Medicine | November 18, 2016 | Volume: 44 | Issue: 12 | Pages: 2251-2257

10.1097/ccm.0000000000002057 | PMID 27858808 Get It

Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity
Yin, Meng , Talwalkar, Jayant A., Oudry, Jennifer, Glaser, Kevin J. , Smyrk, Thomas C. , Miette, Véronique , Sandrin, Laurent , Chen, Jun , Ehman, Richard L. , Miette, Veronique , Yin, Meng

Mayo Clinic

Radiology | November 18, 2016 | Volume: 283 | Issue: 2 | Pages: 418-428

10.1148/radiol.2016160685 | PMID 27861111 Get It

Anatomy and immunochemical characterization of the non-arterial peptidergic diffuse dural innervation of the rat and Rhesus monkey: Implications for functional regulation and treatment in migraine
Rice, Frank L. , Xie, Jennifer Y. , Albrecht, Phillip J. , Acker, Emily , Bourgeois, Justin R. , Navratilova, Edita , Dodick, David W. , Porreca, Frank

Mayo Clinic

Cephalalgia | November 16, 2016 | Volume: 37 | Issue: 14 | Pages: 1350-1372

10.1177/0333102416677051 | PMID 27852962 Get It

Objective The interplay between neuronal innervation and other cell types underlies the physiological functions of the dura mater and contributes to pathophysiological conditions such as migraine. We characterized the extensive, but understudied, non-arterial diffuse dural innervation (DDI) of the rat and Rhesus monkey. Methods We used a comprehensive integrated multi-molecular immunofluorescence labeling strategy to extensively profile the rat DDI and to a lesser extent that of the Rhesus monkey. Results The DDI was distributed across a dense, pervasive capillary network and included free nerve endings of peptidergic CGRP-expressing C fibers that were closely intertwined with noradrenergic (NA) sympathetic fibers and thin-caliber nonpeptidergic “C/Aδ” fibers. These newly identified C/Aδ fibers were unmyelinated, like C fibers, but expressed NF200, usually indicative of Aδ fibers, and uniquely co-labeled for the CGRP co-receptor, RAMP1. Slightly-larger caliber NF200-positive fibers co-labeled for myelin basic protein (MBP) and terminated as unbranched corpuscular endings. The DDI peptidergic fibers co-labeled for the lectin IB4 and expressed presumably excitatory α1-adrenergic receptors, as well as inhibitory 5HT1D receptors and the delta opioid receptor (δOR), but rarely the mu opioid receptor (µOR). Labeling for P2X3, TRPV1, TRPA1, and parasympathetic markers was not observed in the DDI. Interpretation These results suggest potential functional interactions, wherein peptidergic DDI fibers may be activated by stress-related sympathetic activity, resulting in CGRP release that could be detected in the circulation. CGRP may also activate nonpeptidergic C/Aδ fibers that are likely mechanosensitive or polymodal, leading to activation of post-synaptic pain transmission circuits. The distribution of α1-adrenergic receptors, RAMP1, and the unique expression of the δOR on CGRP-expressing DDI fibers suggest strategies for functional modulation and application to therapy.
C1 Myelitis Presenting With Neuralgic Otalgia
Martinez‐Thompson, Jennifer M. , Garza, Ivan , Cutrer, F. Michael , Robertson, Carrie E. , Robertson, Carrie E

Mayo Clinic

Headache: The Journal of Head and Face Pain | November 16, 2016 | Volume: 57 | Issue: 1 | Pages: 126-127

10.1111/head.12988 | PMID 27861805 Get It